Luciano Costa, MD, PhD, Discusses How his Institution Handled the COVID-19 Pandemic

Video

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about how the COVID-19 pandemic affected his work and how they adapted.

At the 2021 International Myeloma Workshop, CancerNetwork® spoke with Luciano Costa, MD, PhD, of O’Neal Comprehensive Cancer Center, about how the COVID-19 pandemic initially impacted clinical trial participation at his institution and how they have since evolved to adapt to a new normal. 

Transcript:

At the beginning of the pandemic, like everybody else, we faced a lot of uncertainty and reacted to that very conservatively. We had an [incremental increase] in telehealth visits, and we established mandatory testing for our invasive procedures. Of course, we implemented universal masking, gloving, and social distancing in our waiting areas and so forth. Thanks to a lot of coordination and hard work from the front-end research and support teams in the front of the institution, we were able to not badly hurt our operations, never stopped taking new patients, and we never stopped therapy of any sorts. [We also] never stopped doing transplant [and] we never stopped enrolling patients into clinical trials. [I’m not saying] that those things have gone normally; especially the clinical trial activities have become very challenging. At the beginning of the pandemic, patients were very reluctant to embrace a new therapy, or embrace uncertainty. They were already surrounded by so much uncertainty of the pandemic itself. Over time, that has gotten a lot better, but there [are] still some challenges from all the turnover that has happened to the workforce. Nowadays, our volumes are normal. We still have some room to improve in terms of normalizing our clinical trial operations.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content